At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 203 enrolled
Drug / intervention
Metformin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Improve PAD Performance With Metformin: The PERMET Trial
In Brief
A Phase 3 clinical trial evaluating Metformin and Placebo for Peripheral Artery Disease. Completed, enrolled 203 participants across 5 sites.
Detailed Summary
The PERMET trial will determine whether metformin daily for six months improves six-minute walk performance in individuals with peripheral artery disease compared to placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeripheral Artery Disease
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 2017
Enrollment StartMay 2017
Primary CompletionAug 2025
Study CompletionNov 2025
TodayJul 2026
First PostedFeb 15, 2017
Enrollment StartMay 23, 2017
Primary CompletionAug 20, 2025
Study CompletionNov 1, 2025
TodayJul 2, 2026
Enrollment to primary: 8.2 yearsPosted 9.4 years ago
Interventions
Metformindrug
Participants will be prescribed up to 2,000 mgs daily of metformin
Placebodrug
Placebo pills will appear identical to the metformin to maintain blinding of participants and investigators.